Jessie Hanrahan
General Counsel at SOLID BIOSCIENCES INC.
Net worth: 57 680 $ as of 31/05/2024
Network origin in Jessie Hanrahan first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 24 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Jessie Hanrahan via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | General Counsel Director of Finance/CFO Sales & Marketing | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Comptroller/Controller/Auditor | |
| QUEST DIAGNOSTICS INCORPORATED | Services to the Health Industry | Corporate Officer/Principal | |
| SAREPTA THERAPEUTICS, INC. | Pharmaceuticals: Major | General Counsel Corporate Officer/Principal Treasurer | |
| MERCK KGAA | Pharmaceuticals: Major | Comptroller/Controller/Auditor | |
The Robert Wood Johnson Foundation
 The Robert Wood Johnson Foundation Investment Trusts/Mutual FundsMiscellaneous The Robert Wood Johnson Foundation (RWJF) is an independent philanthropic organization headquartered in Princeton, New Jersey. The firm was founded in 1972 and is dedicated solely to health. RWJF funds a wide array of programs which are working to help build a national Culture of Health. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| ACORDA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Bioverativ Therapeutics, Inc.
 Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| REATA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| DICERNA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Medocity, Inc.
 Medocity, Inc. Medical/Nursing ServicesHealth Services Medocity, Inc. develops a care platform that bridges the gap between the clinic and the patient?s home. It offers a patient-centric mobile solution that combines key aspects of disease-specific care into a platform that can be used on application and Web-based devices. The firm platform also tracks key symptoms and side effects in real time; displays reports and graphic summaries to understand the patient?s health status on a daily basis. The company is headquartered in Parsippany, NJ. | Medical/Nursing Services | Director/Board Member | |
Compass Therapeutics LLC
 Compass Therapeutics LLC BiotechnologyHealth Technology Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA. | Biotechnology | Director of Finance/CFO | |
| University of California, Los Angeles | College/University | Doctorate Degree | |
| Bentley University | College/University | Graduate Degree | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
| Franklin Pierce College | College/University | Undergraduate Degree | |
| Suffolk University | College/University | Undergraduate Degree | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Doctorate Degree | |
| Princeton University | College/University | Undergraduate Degree Graduate Degree | |
| DAIICHI SANKYO CO., LTD. | Pharmaceuticals: Major | Corporate Officer/Principal | |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Pharmaceuticals: Major | Comptroller/Controller/Auditor | |
| Arthur Anderson & Co. | Corporate Officer/Principal | ||
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Civitas Therapeutics, Inc.
 Civitas Therapeutics, Inc. BiotechnologyHealth Technology Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY. | Biotechnology | Founder Director/Board Member | |
| UNITY BIOTECHNOLOGY, INC. | Biotechnology | Director of Finance/CFO | |
Bain Capital Life Sciences LP
 Bain Capital Life Sciences LP Investment ManagersFinance Bain Capital Life Sciences LP (Bain Capital Life Sciences) is a private equity subsidiary of Bain Capital Private Equity LP, ultimately held by Bain Capital Holdings LP, founded in 2016. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Consultant / Advisor Private Equity Investor | |
| INOZYME PHARMA, INC. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
| FOGHORN THERAPEUTICS INC. | Biotechnology | Director of Finance/CFO Director/Board Member Director/Board Member | |
BiomX Ltd.
 BiomX Ltd. Pharmaceuticals: MajorHealth Technology BiomX Ltd. engages in the development of customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease and colorectalcancer, as well as bacteria that affect the appearance of the skin. The company was founded by Eran Elinav, Timothy K. Lu, and Rotem Sorek on March 3, 2015 and is headquartered in Ness Ziona, Israel. | Pharmaceuticals: Major | Director/Board Member | |
| COVETRUS, INC. | Packaged Software | General Counsel | |
Neurogene, Inc.
 Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | Biotechnology | Director/Board Member | |
| Inheris Pharmaceuticals, Inc. | Director/Board Member | ||
| Breed Nutrition, Inc | Founder | ||
| BIOMX INC. | Biotechnology | Director/Board Member | |
| TAYSHA GENE THERAPIES, INC. | Biotechnology | President | |
KJT Group, Inc.
 KJT Group, Inc. Miscellaneous Commercial ServicesCommercial Services KJT Group, Inc. is an evidence-based research and consulting firm. The private company is based in Rochester, NY. The company was founded in 2007 by Kenneth Tomaszewski. Michaela Gascon has been the CEO of the company since 2007. | Miscellaneous Commercial Services | Director/Board Member | |
Aavantibio, Inc.
 Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Biotechnology | Chief Operating Officer Director/Board Member Director/Board Member Chief Executive Officer Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
SalioGen Therapeutics, Inc.
 SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | Biotechnology | Director/Board Member | |
Jaguar Gene Therapy LLC
 Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a clinical stage biotechnology company based in Lake Forest, IL. Jaguar Gene Therapy LLC is dedicated to accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company has a proven team of experts who have experience in bringing novel gene therapy treatments to patients and their families. Jaguar is rapidly advancing an initial pipeline of three programs, including targeting severe neurodevelopmental disorders, type 1 galactosemia, and type 1 diabetes. The company partner with Advanced Medicine Partners for manufacturing their therapeutics. Key investors include Deerfield Management Company, Arch Venture Partners, and Eli Lilly and Company. The company was founded by Daniel Gallo, and Joseph Nolan has been the CEO since 2020. | Medical/Nursing Services | Chief Tech/Sci/R&D Officer | |
| ARYA SCIENCES ACQUISITION CORP V | Financial Conglomerates | Founder | |
| Boston University School of Medicine | College/University | Corporate Officer/Principal |
Statistics
International
| United States | 44 |
| Israel | 3 |
| Germany | 2 |
| France | 2 |
| Japan | 2 |
Sectoral
| Health Technology | 30 |
| Consumer Services | 9 |
| Health Services | 4 |
| Finance | 4 |
| Miscellaneous | 2 |
Operational
| Director/Board Member | 98 |
| Corporate Officer/Principal | 43 |
| Independent Dir/Board Member | 39 |
| Director of Finance/CFO | 24 |
| Undergraduate Degree | 21 |
Most connected contacts
| Insiders | |
|---|---|
| Adam Koppel | 26 |
| Stephen DiPalma | 24 |
| Ian Smith | 24 |
| Adam Stone | 18 |
| Lynne Sullivan | 16 |
| Raj Shah | 16 |
| Martin Freed | 15 |
| Sukumar Nagendran | 15 |
| Georgia Keresty | 15 |
| Erin Brennan | 9 |
| TY Howton | 8 |
| Alexander Cumbo | 8 |
| Paul Herzich | 8 |
| Clare Khan | 7 |
| Kevin Tan | 7 |
- Stock Market
- Insiders
- Jessie Hanrahan
- Company connections
